A renaissance in marine pharmacology: From preclinical curiosity to clinical reality

Biochemical Pharmacology

Volumn 78, Issue 5, 2009, Pages 440-448

  Glaser, Keith B ^a,b   Mayer, Alejandro M S ^b  

^a ABBOTT LABORATORIES   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Drug discovery; Marine natural products; Marine pharmacology

Indexed keywords

DISCODERMOLIDE; KAINIC ACID; NATURAL PRODUCT; OKADAIC ACID; OMEGA CONOTOXIN MVIIA; SALINOSPORAMIDE A; TALTOBULIN; TETRODOTOXIN; THYMINE ARABINOSIDE; TRABECTEDIN; URACIL ARABINOSIDE;

ARTICLE; BIODIVERSITY; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESEARCH; FUNDING; HIGH THROUGHPUT SCREENING; HUMAN; MARINE ENVIRONMENT; MARINE SPECIES; MEDICAL LITERATURE; MEDICAL RESEARCH; NONHUMAN; PAIN; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

EID: 67649491097     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.04.015     Document Type: Note

References (53)

1. Bergmann W., and Burke D.C. Contributions to the study of marine products. XL. The nucleosides of sponges. IV. Spongosine. J Org Chem 22 (1956) 226-228
2. Bergmann W., and Feeney R.J. Contributions to the study of marine products. XXXII. The nucleosides of sponges. I. J Org Chem 16 (1951) 981-987
3. Bergmann W., and Stempien M.F. Contributions to the study of marine products. XLIII. The nucleosides of sponges. V. The synthesis of spongosine. J Org Chem 22 (1957) 1575-1657
4. Klotz U. Ziconotide-a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain-a short review. Int J Clin Pharmacol Ther 44 (2006) 478-483
5. Schoffski P., Dumez H., Wolter P., Stefan C., Wozniak A., Jimeno J., et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 9 (2008) 1609-1618
6. Faulkner D.J. Marine natural products. Nat Prod Rep 17 (2000) 7-55
7. Faulkner D.J. Marine natural products. Nat Prod Rep 18 (2001) 1-49
8. Faulkner D.J. Marine natural products. Nat Prod Rep 19 (2002) 1-48
9. Blunt J.W., Copp B.R., Hu W.P., Munro M.H., Northcote P.T., and Prinsep M.R. Marine natural products. Nat Prod Rep 24 (2007) 31-86
10. Blunt J.W., Copp B.R., Hu W.P., Munro M.H., Northcote P.T., and Prinsep M.R. Marine natural products. Nat Prod Rep 25 (2008) 35-94
11. Blunt J.W., Copp B.R., Munro M.H., Northcote P.T., and Prinsep M.R. Marine natural products. Nat Prod Rep 20 (2003) 1-48
12. Blunt J.W., Copp B.R., Munro M.H., Northcote P.T., and Prinsep M.R. Marine natural products. Nat Prod Rep 21 (2004) 1-49
13. Blunt J.W., Copp B.R., Munro M.H., Northcote P.T., and Prinsep M.R. Marine natural products. Nat Prod Rep 22 (2005) 15-61
14. Blunt J.W., Copp B.R., Munro M.H., Northcote P.T., and Prinsep M.R. Marine natural products. Nat Prod Rep 23 (2006) 26-78
15. Mayer A.M.S., and Gustafson K.R. Marine pharmacology in 2000: antitumor and cytotoxic compounds. Int J Cancer 105 (2003) 291-299
16. Mayer A.M.S., and Gustafson K.R. Marine pharmacology in 2001-2: antitumour and cytotoxic compounds. Eur J Cancer 40 (2004) 2676-2704
17. Mayer A.M.S., and Gustafson K.R. Marine pharmacology in 2003-2004: anti-tumour and cytotoxic compounds. Eur J Cancer 42 (2006) 2241-2270
18. Mayer A.M.S., and Gustafson K.R. Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds. Eur J Cancer 44 (2008) 2357-2387
19. Mayer A.M.S., and Hamann M.T. Marine pharmacology in 1999: compounds with antibacterial, anticoagulant, antifungal, anthelmintic, anti-inflammatory, antiplatelet, antiprotozoal and antiviral activities affecting the cardiovascular, endocrine, immune and nervous systems, and other miscellaneous mechanisms of action. Comp Biochem Physiol C: Toxicol Pharmacol 132 (2002) 315-339
20. Mayer A.M.S., and Hamann M.T. Marine pharmacology in 2000: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antituberculosis, and antiviral activities; affecting the cardiovascular, immune, and nervous systems and other miscellaneous mechanisms of action. Mar Biotechnol (NY) 6 (2004) 37-52
21. Mayer A.M.S., and Hamann M.T. Marine pharmacology in 2001-2002: marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems and other miscellaneous mechanisms of action. Comp Biochem Physiol C: Toxicol Pharmacol 140 (2005) 265-286
22. Mayer A.M.S., and Lehmann V.K.B. Marine pharmacology in 1999: antitumor and cytotoxic compounds. Anticancer Res 21 (2001) 2489-2500
23. Mayer A.M.S., Rodriguez A.D., Berlinck R.G., and Hamann M.T. Marine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Comp Biochem Physiol C: Toxicol Pharmacol 145 (2007) 553-581
24. Mayer A.M.S. Marine pharmacology in 1998: antitumor and cytotoxic compounds. The Pharmacologist 41 (1999) 159-164
25. Mayer A.M.S., Rodriguez A.D., Berlinck R.G., and Hamann M.T. Marine pharmacology in 2005-6: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antituberculosis, and antiviral activities; affecting the cardiovascular, immune, and nervous systems and other miscellaneous mechanisms of action. Biochim Biophys Acta 1790 (2009) 283-308
26. Mayer A.M.S., and Lehmann V.K.B. Marine pharmacology in 1998: marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antituberculosis, and antiviral activities; affecting the cardiovascular, immune, and nervous systems and other miscellaneous mechanisms of action. The Pharmacologist 42 (2000) 62-69
27. Koehn F.E. High impact technologies for natural products screening. Prog Drug Res 65 175 (2008) 7-210
28. Faulkner D.J. Marine pharmacology. Antonie Van Leeuwenhoek 77 (2000) 135-145
29. Simmons T.L., Andrianasolo E., McPhail K., Flatt P., and Gerwick W.H. Marine natural products as anticancer drugs. Mol Cancer Ther 4 (2005) 333-342
30. Molinski T.F., Dalisay D.S., Lievens S.L., and Saludes J.P. Drug development from marine natural products. Nat Rev Drug Discov 8 (2009) 69-85
31. Bull A.T., and Stach J.E. Marine actinobacteria: new opportunities for natural product search and discovery. Trends Microbiol 15 (2007) 491-499
32. Konig G.M., Kehraus S., Seibert S.F., Abdel-Lateff A., and Muller D. Natural products from marine organisms and their associated microbes. Chembiochem 7 (2006) 229-238
33. Lipp J.S., Morono Y., Inagaki F., and Hinrichs K.U. Significant contribution of Archaea to extant biomass in marine subsurface sediments. Nature 454 (2008) 991-994
34. Singh S.B., and Pelaez F. Biodiversity, chemical diversity and drug discovery. Prog Drug Res 65 141 (2008) 3-74
35. Newman D.J., and Hill R.T. New drugs from marine microbes: the tide is turning. J Ind Microbiol Biotechnol 33 (2006) 539-544
36. Saleem M., Ali M.S., Hussain S., Jabbar A., Ashraf M., and Lee Y.S. Marine natural products of fungal origin. Nat Prod Rep 24 (2007) 1142-1152
37. Tan L.T. Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry 68 (2007) 954-979
38. Hopwood D.A. Therapeutic treasures from the deep. Nat Chem Biol 3 (2007) 457-458
39. Udwary D.W., Zeigler L., Asolkar R.N., Singan V., Lapidus A., Fenical W., et al. Genome sequencing reveals complex secondary metabolome in the marine actinomycete Salinispora tropica. Proc Natl Acad Sci USA 104 (2007) 10376-10381
40. Olivera B.M. Conus peptides: biodiversity-based discovery and exogenomics. J Biol Chem 281 (2006) 31173-31177
41. Olivera B.M., and Teichert R.W. Diversity of the neurotoxic Conus peptides: a model for concerted pharmacological discovery. Mol Interv 7 (2007) 251-260
42. Jaspars M. Innovative mechanisms for tackling antibacterial resistance. Royal Society Policy Document 14/08.
43. Grabowski K., Baringhaus K.H., and Schneider G. Scaffold diversity of natural products: inspiration for combinatorial library design. Nat Prod Rep 25 (2008) 892-904
44. Battershill C.N., Bavington C., Chahal S., Jaspars M., Littlechild J., and Mearns-Spragg A. Contributions of marine bioscience to industrial biotechnology. Ind Biotechnol 3 (2007) 304-310
45. Wright S.H., Raab A., Tabudravu J.N., Feldmann J., Long P.F., Battershill C.N., et al. Marine metabolites and metal ion chelation: intact recovery and identification of an iron(II) complex in the extract of the ascidian Eudistoma gilboviride. Angew Chem Int Ed Engl 47 (2008) 8090-8092
46. Folmer F., Houssen W.E., Scott R.H., and Jaspars M. Biomedical research tools from the seabed. Curr Opin Drug Discov Devel 10 (2007) 145-152
47. Lang G., Mayhudin N.A., Mitova M.I., Sun L., van der Sar S., Blunt J.W., et al. Evolving trends in the dereplication of natural product extracts: new methodology for rapid, small-scale investigation of natural product extracts. J Nat Prod 71 (2008) 1595-1599
48. Bugni T.S., Richards B., Bhoite L., Cimbora D., Harper M.K., and Ireland C.M. Marine natural product libraries for high-throughput screening and rapid drug discovery. J Nat Prod 71 (2008) 1095-1098
49. Nogle L.M., Gerwick W.H., and Somocystinamide A. A novel cytotoxic disulfide dimer from a Fijian marine cyanobacterial mixed assemblage. Org Lett 4 (2002) 1095-1098
50. Wrasidlo W., Mielgo A., Torres V.A., Barbero S., Stoletov K., Suyama T.L., et al. The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. Proc Natl Acad Sci USA 105 (2008) 2313-2318
51. Fenical W., Jensen P.R., Palladino M.A., Lam K.S., Lloyd G.K., and Potts B.C. Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg Med Chem (2008)
52. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., and Fenical W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 42 (2003) 355-357
53. Bailly C. Ready for a comeback of natural products in oncology. Biochem Pharmacol 77 (2009) 1447-1457